BIEL BioElectronics Corp.

Update: BioElectronics Announces Publication of a Study of the ActiPatch Medical Device as an Effective Long-Term Treatment for Chronic Pain

Update: BioElectronics Announces Publication of a Study of the ActiPatch Medical Device as an Effective Long-Term Treatment for Chronic Pain

FREDERICK, MD, Oct. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL) , the maker of non-invasive electroceutical devices, is pleased to announce the publication of a study in the journal Pain Research and Management, titled “A Prospective Six-Month Study of Chronic Pain Sufferers: A Novel OTC Neuromodulation Therapy”. The study demonstrated that users who experience pain relief after using ActiPatch® for 7 days, continued to experience this relief over at least 6 months when ActiPatch® use is continued.

The Study Key Points:

  •  240 Subjects were recruited into 6-month study of 7-day trial users of the ActiPatch medical device to treat chronic pain.
  •  7 days after initial treatment, average pain was reduced by 65%, from 8.2 to 2.9 on a 0-10 visual analog scale (VAS).
  •  At the 6-month measurement, the average VAS was 3.3, indicating a 60% pain reduction from baseline.
  •  Sustained pain relief translated into improved quality of life and reduced medication use for the majority of the subjects.

The publication is Open Access and can be viewed at: .

The article was authored by Dr. Richard Staelin, Ph.D. of Duke University, Dr. Ian Rawe, Ph.D., Director of Clinical Research at BioElectronics and Dr. Sree Koneru, Ph.D., VP of Product Development at BioElectronics. “While many pain treatments provide short term relief, there is little data on maintaining long-term effectiveness. This study is therefore significant as it shows that that ActiPatch is not only highly effective in the short term (7 days), but maintains treatment effectiveness over at least 6 months in a majority of subjects,” said Dr. Rawe.

About BioElectronics Corporation

BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy.

For more information, please visit .

Contact Paul Knopick

940.262.3584

EN
03/10/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioElectronics Corp.

 PRESS RELEASE

Sree Koneru, PhD Joins the Board of Directors of BioElectronics Corpor...

Sree Koneru, PhD Joins the Board of Directors of BioElectronics Corporation FREDERICK, Md., Dec. 03, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation ( OTC: BIEL, a developer of medical technology products, today announces that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD. "We are honored to welcome Sree Koneru to the Board. Sree brings a rich depth of experience in medical device developm...

 PRESS RELEASE

BioElectronics Corporation's Chairman Updates Investors

BioElectronics Corporation's Chairman Updates Investors Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD. Dear Shareholders, It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant. Current Medical (RecoveryRx) Sales Although our RecoveryRx product is well ac...

 PRESS RELEASE

BioElectronics Corporation Announces the Publication of a Canine Arthr...

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study 96% of the Dogs Treated With the Active Model 088 Device Showed Marked Improvement FREDERICK, MD, March 25, 2024 (GLOBE NEWSWIRE) -- via -- BioElectronics Corporation ( OTC: BIEL) a developer of medical technology products, announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT)device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed ...

 PRESS RELEASE

BioElectronics Corporation Announces the Publication of Pilot Study Re...

BioElectronics Corporation Announces the Publication of Pilot Study Results Beneficial Treatment Effect for Phantom and Residual Limb Pain Identified FREDERICK, MD, Feb. 23, 2024 (GLOBE NEWSWIRE) -- via – BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device. "Treating intractable postamputation pain with wearable, non-invasive, non-thermal, pulsed shortwave (radiofrequency) therapy: a randomized, double-ma...

 PRESS RELEASE

BioElectronics Chairman Updates Investors

BioElectronics Chairman Updates Investors Discusses Clinical Trial Progress and Potential Legal Action Against MundiPharma FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via – BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD. The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans.  As I have mentioned many times, I believe our strategic m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch